Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	Aclaris Therapeutics	Antibe Therapeutics	Antibe Therapeutics	Supernus Pharmaceuticals	PMV Pharmaceuticals
Symbol	NASDAQ:ACRS	NASDAQ:ATBPD	OTCMKTS:ATBPD	NASDAQ:SUPN	NASDAQ:PMVP
Price Information
Current Price	$22.95	$3.64	$3.64	$29.37	$35.00
52 Week Range	Buy	N/A	N/A	Buy	Buy
MarketRank™
Overall Score	0.8	0.1	0.1	1.9	1.2
Analysis Score	0.0	0.0	0.0	3.5	1.4
Community Score	2.6	0.0	0.0	3.0	2.9
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.8	0.0	0.0	1.7	1.7
Earnings & Valuation Score	0.6	0.6	0.6	1.3	0.0
Analyst Ratings
Consensus Recommendation	Buy	N/A	N/A	Buy	Buy
Consensus Price Target	N/A	N/A	N/A	$37.50	$38.00
% Upside from Price Target	N/A	N/A	N/A	27.68% upside	8.57% upside
Trade Information
Market Cap	$1.20 billion	$1.41 billion	$1.41 billion	$1.56 billion	$1.57 billion
Beta	1.2	0.57	0.57	1.38	N/A
Average Volume	2,286,862	29,710	29,710	580,509	154,050
Sales & Book Value
Annual Revenue	$4.23 million	$7.51 million	$7.51 million	$392.76 million	N/A
Price / Sales	282.59	187.57	187.57	3.96	N/A
Cashflow	N/A	N/A	N/A	$2.60 per share	N/A
Price / Cash	N/A	N/A	N/A	11.30	N/A
Book Value	$1.69 per share	$0.10 per share	$0.10 per share	$11.35 per share	N/A
Price / Book	13.58	36.40	36.40	2.59	N/A
Profitability
Net Income	$-161,350,000.00	$-14,540,000.00	$-14,540,000.00	$113.06 million	N/A
EPS	($2.25)	($0.50)	($0.50)	$2.10	N/A
Trailing P/E Ratio	N/A	N/A	N/A	12.19	0.00
Forward P/E Ratio	N/A	N/A	N/A	18.59	N/A
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-941.07%	-273.96%	-273.96%	27.09%	N/A
Return on Equity (ROE)	-104.00%	-176.23%	-150.49%	20.02%	N/A
Return on Assets (ROA)	-64.47%	-106.91%	-98.51%	9.67%	N/A
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	0.26%	N/A	N/A	0.53%	N/A
Current Ratio	4.54%	6.55%	5.97%	1.84%	N/A
Quick Ratio	4.54%	5.95%	5.42%	1.70%	N/A
Ownership Information
Institutional Ownership Percentage	59.10%	N/A	N/A	96.11%	69.72%
Insider Ownership Percentage	8.20%	N/A	N/A	6.57%	N/A
Miscellaneous
Employees	57	47	47	563	44
Shares Outstanding	52.09 million	387.00 million	387.00 million	53.02 million	44.93 million
Next Earnings Date	8/6/2021 (Estimated)	N/A	N/A	8/17/2021 (Estimated)	6/2/2021 (Estimated)
Optionable	Optionable	Not Optionable	Not Optionable	Optionable	Not Optionable

Source	Headline
	PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) CFO Winston Kung Sells 4,500 Shares americanbankingnews.com - May 5 at 4:34 AM
	We're Interested To See How PMV Pharmaceuticals (NASDAQ:PMVP) Uses Its Cash Hoard To Grow nasdaq.com - May 2 at 2:24 PM
	PMV Pharmaceuticals (NASDAQ:PMVP) Sees Unusually-High Trading Volume americanbankingnews.com - April 28 at 12:38 PM
	PMV Pharmaceuticals (NASDAQ:PMVP) Trading Down 4.7% americanbankingnews.com - April 27 at 11:58 AM
	PMV Pharmaceuticals (NASDAQ:PMVP) Sees Strong Trading Volume americanbankingnews.com - April 22 at 11:59 AM
	PMV Pharmaceuticals (NASDAQ:PMVP) Shares Gap Up to $31.26 americanbankingnews.com - April 21 at 12:54 PM
	Abeona Therapeutics Appoints Two Industry Leaders as New Independent Members to Its Board of Directors benzinga.com - April 19 at 7:35 AM
	PMV Pharmaceuticals (NASDAQ:PMVP) Sees Large Volume Increase americanbankingnews.com - April 15 at 11:40 AM
	Pmv Pharmaceuticals Inc (PMVP) investing.com - April 12 at 12:40 AM
	PMV Pharma Presents Late-Breaking Preclinical... benzinga.com - April 10 at 6:16 PM
	PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the ... apnews.com - April 10 at 6:16 PM
	PMV Pharmaceuticals Inc. [PMVP] is -46.33% lower this YTD. Is it still time to buy? dbtnews.com - March 25 at 11:09 PM
	PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Down Almost -10.23% in 1 Month, But Long Term Looking Good marketingsentinel.com - March 25 at 1:07 PM
	PMV Pharmaceuticals Announces Presentation of PC14586 Preclinical Data at the American ... apnews.com - March 11 at 7:59 AM
	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate ... apnews.com - March 4 at 3:38 AM
	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Nasdaq:PMVP compsmag.com - March 3 at 10:37 PM
	PMV Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights finance.yahoo.com - March 3 at 5:35 PM
	PMV Pharma Appoints p53 Pioneer Dr. Guillermina Lozano to Scientific Advisory Board finance.yahoo.com - February 16 at 9:14 AM
	We're Not Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn finance.yahoo.com - December 25 at 3:10 PM
	Is PMVP A Good Stock To Buy Now? finance.yahoo.com - December 16 at 7:39 PM
	PMV Pharmaceuticals to Present at Evercore ISI 3rd Annual HealthCONx Conference finance.yahoo.com - November 24 at 7:14 PM
	PMV Pharma Doses First Patient in Phase 1/2 Study of PC14586, a First-in-Class Precision Oncology Therapy That Targets Mutant p53 finance.yahoo.com - November 23 at 12:59 PM
	PMV Pharmaceuticals Reports Third Quarter 2020 Financial Results and Corporate Highlights finance.yahoo.com - November 13 at 8:55 AM
	PMV Pharmaceuticals Inc. barrons.com - November 1 at 12:37 PM
	PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation finance.yahoo.com - October 24 at 12:42 AM

Date	Company	Brokerage	Action
4/27/2021	Aclaris Therapeutics	HC Wainwright	Initiated Coverage
1/2/2020	Aclaris Therapeutics	SVB Leerink	Reiterated Rating
10/11/2019	Aclaris Therapeutics	William Blair	Reiterated Rating
9/6/2019	Aclaris Therapeutics	JMP Securities	Downgrade
8/9/2019	Aclaris Therapeutics	Cantor Fitzgerald	Reiterated Rating
4/19/2021	Supernus Pharmaceuticals	Jefferies Financial Group	Upgrade
2/3/2021	Supernus Pharmaceuticals	Piper Sandler	Boost Price Target
4/16/2020	Supernus Pharmaceuticals	Stifel Nicolaus	Lower Price Target
11/8/2019	Supernus Pharmaceuticals	Berenberg Bank	Downgrade
8/7/2019	Supernus Pharmaceuticals	Cowen	Set Price Target
8/7/2019	Supernus Pharmaceuticals	Mizuho	Reiterated Rating
3/4/2019	Supernus Pharmaceuticals	B. Riley	Set Price Target
1/16/2019	Supernus Pharmaceuticals	Piper Jaffray Companies	Set Price Target
10/20/2020	PMV Pharmaceuticals	Evercore ISI	Initiated Coverage
10/20/2020	PMV Pharmaceuticals	Bank of America	Initiated Coverage
10/20/2020	PMV Pharmaceuticals	The Goldman Sachs Group	Initiated Coverage

(Data available from 5/9/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources